Labcorp stock forecast 2027–2029
MyStockButler's October 2026 analysis: The weighted forecast puts Labcorp at $352.44 in October 2027 and $419.26 in October 2029, across 25% bear, 55% base, and 20% bull cases. It hinges on growth converting into margins and cash.
Where could Labcorp's shares be by 2029?
The weighted forecast is nearly flat after one year, then compounds to a modest gain. It puts LabCorp at $352.44 in October 2027, or a 1% loss including dividends, $382.92 in October 2028, or an 8% gain, and $419.26 in October 2029, or a 19% gain. The 2029 range is wide: $238.05 in the bear case to $606.45 in the bull case, against today’s $360.25. The probabilities are 25% bear, 55% base, and 20% bull.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 277.56 (-22 %) | 253.73 (-28 %) | 238.05 (-32 %) |
| Base | 55 % | 361.60 (+1 %) | 396.52 (+12 %) | 433.56 (+23 %) |
| Bull | 20 % | 420.87 (+18 %) | 506.99 (+42 %) | 606.45 (+71 %) |
| Weighted | 100 % | 352.44 (-1 %) | 382.92 (+8 %) | 419.26 (+19 %) |
What this means. The weighted row is the probability-based average of the bear, base, and bull cases, not a guaranteed share price.
What has to go right or wrong for Labcorp's forecast?
The weighted case points to a 1% loss by October 2027 and a 19% gain by October 2029, hinging on growth converting into margins and cash. Adjusted EPS guidance is $18.30–$18.70. Labcorp guides free cash flow to $1,240 million–$1,360 million. Through 2029, it targets annual revenue growth of 5%–8% and adjusted-EPS growth of 8.5%–11.5%.
The bear case uses 3% revenue growth and declining margins because preliminary 2027 reimbursement rates imply a $125 million impact before offsets, while study delays could slow BLS conversion. The bull case uses 7.5% growth and expanding margins because requisitions rose 4.8%, Diagnostics revenue rose 6.5%, and BLS book-to-bill reached 1.10x. Management’s record of meeting or beating initial guidance in 10 of 12 comparable metric-years supports the base, but acquisitions and reimbursement pressure prevent greater confidence.
How much cash does Labcorp really make?
Operating cash was $1.64 billion in 2025. After $434.5 million of capital spending, free cash flow was $1.21 billion. Subtracting $125.8 million of stock-based pay leaves $1.08 billion under the table’s “real free cash flow” convention.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 1,640.5 | 1,585.8 | 1,202.3 | 1,764.8 | 2,846.3 |
| − Capital spending | 434.5 | 489.9 | 453.6 | 429.3 | 421.5 |
| = Free cash flow | 1,206.0 | 1,095.9 | 748.7 | 1,335.5 | 2,424.8 |
| − Stock pay | 125.8 | 116.7 | 128.7 | 116.8 | 132.9 |
| = Real free cash flow | 1,080.2 | 979.2 | 620.0 | 1,218.7 | 2,291.9 |
What this means. The company's own free cash flow matches ours except in 2021, when its published figure was rounded down by 24.8 million, not because it counted another cash cost.
What does an investor pay for Labcorp today?
P/E compares the share price with earnings per share. The trailing figure uses earnings already produced; the forward figure uses an estimate of future earnings. A lower forward P/E therefore assumes that earnings will rise. That rise might come from genuine growth, cost savings, acquisitions, or a different definition of earnings, so the investor is paying for delivery, not merely for Labcorp to repeat its recent results.
| Today (Oct 29, 2026) | |
|---|---|
| Share price | 360.25 |
| Market value (calculated) | 29,252.3 |
| Enterprise value (calculated) | 34,908.7 |
| P/E, last 12 months (calculated) | 29.6x |
| P/E, next 12 months (calculated) | 18.2x |
| Real free cash flow yield (calculated) | 3.7% |
What this means. Enterprise value includes the company's debt and subtracts its cash, so it shows what the whole business would cost rather than just the shares.